Skip to content


Xolair (omalizumab) is an antibody pharmaceutical. Omalizumab was first approved as Xolair on 2003-06-20. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma and urticaria. The pharmaceutical is active against Immunoglobulin heavy constant epsilon.
Trade Name Xolair
Common Name Omalizumab
Indication asthma, urticaria
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now